HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS

INTRODUCTION: We have observed that approximately 26% of recurrent gliomas acquire hypermutation following treatment with temozolomide (TMZ). Intriguingly, 91% of these tumors harbor mutations in mismatch repair (MMR) genes. Strategies to target MMR-deficient gliomas thus stand to impact a large num...

Descripción completa

Detalles Bibliográficos
Autores principales: Boynton, Adam, Pal, Sangita, Touat, Mehdi, Currimjee, Naomi, Qian, Kenin, Bellamy, Charlotte, Ho, Patricia, Berstler, Jim, Ligon, Keith, Beroukhim, Rameen, Bandopadhayay, Pratiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
High Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715373/
http://dx.doi.org/10.1093/neuonc/noaa222.314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715373/
http://dx.doi.org/10.1093/neuonc/noaa222.314

Ejemplares similares